Related Articles for PubMed (Select 16417649)

New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines.

Crowe DL, Lee MK.

Breast Cancer Res. 2006;8(1):R1. Epub 2005 Dec 9.

PMID: 16417649 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Cancer Res. 2002 Jan 1;62(1):141-51.

PMID: 11782371 [PubMed - indexed for MEDLINE]

Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.

Mamon HJ, Dahlberg W, Azzam EI, Nagasawa H, Muto MG, Little JB.

Int J Radiat Biol. 2003 Oct;79(10):817-29.

PMID: 14630541 [PubMed - indexed for MEDLINE]

TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage.

Dubrovska A, Kanamoto T, Lomnytska M, Heldin CH, Volodko N, Souchelnytskyi S.

Oncogene. 2005 Mar 31;24(14):2289-97.

PMID: 15735739 [PubMed - indexed for MEDLINE]

Coactivator-mediated estrogen response in human squamous cell carcinoma lines.

Ku TK, Crowe DL.

J Endocrinol. 2007 Apr;193(1):147-55.

PMID: 17400812 [PubMed - indexed for MEDLINE]

The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.

Rousseau C, Pettersson F, Couture MC, Paquin A, Galipeau J, Mader S, Miller WH Jr.

J Steroid Biochem Mol Biol. 2003 Jul;86(1):1-14.

PMID: 12943740 [PubMed - indexed for MEDLINE]

Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.

Jaber BM, Mukopadhyay R, Smith CL.

J Mol Endocrinol. 2004 Feb;32(1):307-23.

PMID: 14766010 [PubMed - indexed for MEDLINE]

Emerging roles of BRCA1 in transcriptional regulation and DNA repair.

Chen Y, Lee WH, Chew HK.

J Cell Physiol. 1999 Dec;181(3):385-92. Review.

PMID: 10528224 [PubMed - indexed for MEDLINE]

Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.

Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, Shen CY.

Cancer Res. 2004 Jul 15;64(14):5013-9.

PMID: 15256476 [PubMed - indexed for MEDLINE]

10:

Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG.

Cancer Res. 2005 Aug 1;65(15):6557-67.

PMID: 16061635 [PubMed - indexed for MEDLINE]

11:

BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.

Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM.

Oncogene. 1998 Jun 11;16(23):3069-82.

PMID: 9662340 [PubMed - indexed for MEDLINE]

12:

Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.

Yuan R, Fan S, Wang JA, Meng Q, Ma Y, Schreiber D, Goldberg ID, Rosen EM.

Prostate. 1999 Jun 15;40(1):37-49.

PMID: 10344722 [PubMed - indexed for MEDLINE]

13:

The pure estrogen receptor antagonist ICI 182,780 promotes a novel interaction of estrogen receptor-alpha with the 3',5'-cyclic adenosine monophosphate response element-binding protein-binding protein/p300 coactivators.

Jaber BM, Gao T, Huang L, Karmakar S, Smith CL.

Mol Endocrinol. 2006 Nov;20(11):2695-710. Epub 2006 Jul 13.

PMID: 16840538 [PubMed - indexed for MEDLINE]

14:

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.

Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK.

J Biol Chem. 2000 Aug 4;275(31):23899-903.

PMID: 10843985 [PubMed - indexed for MEDLINE]

15:

Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.

Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM.

Oncogene. 1998 Apr 30;16(17):2229-41.

PMID: 9619832 [PubMed - indexed for MEDLINE]

16:

Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.

Wang H, Zeng ZC, Bui TA, DiBiase SJ, Qin W, Xia F, Powell SN, Iliakis G.

Cancer Res. 2001 Jan 1;61(1):270-7.

PMID: 11196174 [PubMed - indexed for MEDLINE]

17:

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID: 18473729 [PubMed - indexed for MEDLINE]

18:

Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.

Au WW, Henderson BR.

Cell Signal. 2007 Sep;19(9):1879-92. Epub 2007 May 1.

PMID: 17531442 [PubMed - indexed for MEDLINE]

19:

p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha.

Fritah A, Saucier C, Mester J, Redeuilh G, Sabbah M.

Mol Cell Biol. 2005 Mar;25(6):2419-30.

PMID: 15743834 [PubMed - indexed for MEDLINE]

Recent Activity